Skip to main content
. 2024 Jun 19;14(6):726. doi: 10.3390/biom14060726

Figure 8.

Figure 8

Necrosulfonamide (NSA) treatment does not affect body weight gain, lipid levels, or blood pressure in experimental abdominal aortic aneurysms. (A) Body weight in vehicle- and NSA-treated apolipoprotein E-deficient mice at the baseline (day 0) and 28 days after angiotensin (Ang) II infusion. (B,C) Serum levels of total cholesterol (B) and triglycerides (C) from vehicle- and NSA-treated apolipoprotein E-deficient mice 28 days after Ang II infusion. (D,E) Systolic (D) and diastolic (E) blood pressure of vehicle- and NSA-treated apolipoprotein E-deficient mice at the baseline and 28 days after Ang II infusion. All data are presented as the mean ± standard deviation. Two-way analysis of variance test (A,D,E) or Student’s t test (B,C) showed no significant difference between the two treatment groups at the same timepoint.